Investment Thesis
Pacira BioSciences exhibits severely compressed profitability with 1.6% net margins and minimal ROE/ROA, indicating fundamental operational challenges despite adequate revenue base. The company carries substantial leverage ($367.7M long-term debt) with tight interest coverage (1.9x), leaving little margin for error; while free cash flow is positive, the tight debt service burden limits financial flexibility.
Strengths
- Strong liquidity position with 4.73x current ratio and $144.3M cash
- Positive free cash flow generation of $23M with 12.9% FCF margin despite low net profitability
- Low capital intensity (2.7M capex) indicates relatively asset-light operations
Risks
- Critically low profitability: 1.6% net margin and 3.9% operating margin insufficient for a pharmaceutical company
- Severe capital inefficiency with 0.4% ROE and 0.2% ROA indicating value destruction
- Elevated leverage risk: 1.9x interest coverage is dangerously tight; high debt-to-equity of 0.56x limits strategic flexibility
- Anemic revenue growth at 3.6% YoY is inadequate for sustainable debt service
Key Metrics to Watch
- Operating margin trend and path to 10%+ profitability
- Interest coverage ratio - must improve above 2.5x to reduce refinancing risk
- Revenue growth acceleration above 5% to support debt burden
Financial Metrics
Revenue
177.4M
Net Income
2.9M
EPS (Diluted)
$0.07
Free Cash Flow
23.0M
Total Assets
1.2B
Cash
144.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
3.9%
Net Margin
1.6%
ROE
0.4%
ROA
0.2%
FCF Margin
12.9%
Balance Sheet & Liquidity
Current Ratio
4.73x
Quick Ratio
3.35x
Debt/Equity
0.56x
Debt/Assets
45.9%
Interest Coverage
1.87x
Long-term Debt
367.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:34:54.052143 |
Data as of: 2026-03-31 |
Powered by Claude AI